High levels of TIMP-2 correlate with adverse prognosis in breast cancer.

Abstract

TIMP-2 is an endogenous inhibitor of MMPs. Most data from model systems suggest that high levels of this inhibitor prevent metastasis. In human breast cancers, however, we show that high levels of TIMP-2 correlate with both shortened disease-free interval and overall survival. In primary breast cancers, TIMP-2 levels showed no significant relationship with either tumor size or axillary node status but correlated inversely with estrogen receptor levels. TIMP-2 levels also correlated significantly with those for TIMP-1. We conclude that high levels of endogenous TIMP-2, like other protease inhibitors such as PAI-1 and TIMP-1, correlate with progression of human breast cancer.

• Authors: A Remacle, K McCarthy, A Noël, T Maguire, E McDermott, N O'Higgins, J M Foidart, M J Duffy
• Journal: International journal of cancer (Int J Cancer) Vol. 89 Issue 2 Pg. 118-21 (Mar 20 2000) ISSN: 0020-7136 [Print] United States
• PMID: 10756061 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2000 Wiley-Liss, Inc.

Chemical References

• Biomarkers, Tumor
• Matrix Metalloproteinase Inhibitors
• Tissue Inhibitor of Metalloproteinase-1
• Tissue Inhibitor of Metalloproteinase-2

Topics

• Biomarkers, Tumor (metabolism)
• Breast Neoplasms (metabolism)
• Disease-Free Survival
• Enzyme-Linked Immunosorbent Assay
• Female
• Humans
• Matrix Metalloproteinase Inhibitors
• Prognosis
• Survival Analysis
• Tissue Inhibitor of Metalloproteinase-1 (metabolism)
• Tissue Inhibitor of Metalloproteinase-2 (metabolism)